South Korean botulinum toxin A crosses major revenue threshold, validating regional demand and manufacturing scale.
Daewoong Pharmaceuticals announced that Nabota (botulinum toxin type A) has achieved cumulative sales exceeding 1 trillion won (approximately $750 million USD), a milestone underscoring the Korean toxin maker's penetration in Asian markets and growing export presence.
Nabota competes primarily in Asia-Pacific and select European markets, where it has built strong relationships with practitioners and medical spas. The milestone reflects both volume growth and pricing power in regions where Allergan's Botox faces less regulatory entrenchment and where practitioners seek alternatives with competitive rebate structures.
Nabota's 1 trillion won milestone demonstrates that non-Allergan toxins can achieve significant scale in competitive markets.
For US-based medspa owners, Nabota remains a secondary player, but the milestone signals that non-Allergan toxins can achieve scale and profitability. If Daewoong or its distributors expand US market access—particularly through direct-to-practice channels—expect pricing pressure on established brands.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
